Categories
Digital Health MedTech

Best Countries to Launch or Scale a HealthTech Startup in Europe (2025)

Where the regulations help, the funding flows, and the pilots don’t take geological time

If you ask ten founders where to launch a healthtech startup in Europe, eight will say Berlin, one will say London, and one will whisper Lisbon for “quality of life reasons”. They’re all partially right and all are missing the bigger picture.

Europe isn’t one market. It’s 27 regulatory fiefdoms, three reimbursement philosophies, and a few hundred interpretations of GDPR. Your success depends less on your pitch deck and more on which country actually wants what you’ve built.

Below is your 2025 market map, written for people who need real answers: founders choosing their first market, investors analysing expansion, and operator-types who enjoy pain.

1. France

The most healthtech-friendly major market in Europe

Why France works

  • Strong government buy-in for digital health.
  • Funding muscle: Bpifrance, EU4Health, France 2030.
  • Single-payer structure = easier national rollout.
  • PECAN (the DiGA-like pathway) actually works.

Best for

Digital care delivery, AI diagnostics, practice management, DTx reimbursement plays.

Funding & Launchpads

Example Startup

Doctolib Valuation: ~€6.4B
The poster child of French digital health integration.

Caveat

French bureaucracy moves fast, but only after explaining for 6 months why it cannot. Labour laws are very strict and unions strong.

2. The Nordics (Sweden, Finland, Denmark)

Small markets, big efficiency

Why the Nordics work

  • Public systems open to innovation.
  • Culturally high trust → smoother adoption of data-heavy tools.
  • A disproportionate number of EU healthtech winners.

Best for

Remote monitoring, diagnostics, preventive health, virtual primary care, health data infrastructure.

Funding & Launchpads

Example Startups

  • Oura (Finland) Valuation ~$5.2B
  • Kry (Sweden) Valuation ~$2B
  • Neko Health (Sweden) Valuation ~$1.8B

Caveat

Great for pilots; too small for scale unless you go south quickly, as Medicover AB and Oura did.

3. United Kingdom

Chaotic, political, commercially attractive

Why the UK works

  • One of Europe’s strongest funding ecosystems.
  • Private healthcare uptake at record highs.
  • NHS validation still opens doors — globally.
  • London remains Europe’s top hub for digital health + AI research.

Best for

AI health, care coordination, chronic-care platforms, consumer-forward health apps.

Funding & Launchpads

Example Startups

Caveat

The NHS is ambitious and inspiring… and also a timeline graveyard. Dual-market GTM (NHS + private) is mandatory.

4. Germany

Complicated, wealthy, occasionally glorious

Why Germany works

  • Biggest healthcare budget in Europe.
  • Strong reimbursement mechanisms (once you’re “in”).
  • Serious medtech and pharma industry footprint.

Best for

Class II/III devices, diagnostics, hospital workflow software, B2B2C employer models.

Funding & Launchpads

Example Startup

No German healthtech unicornst that I would be awarte of yet… but Ada Health came close (est. ~$300M valuation).

Caveat

Germany will adopt your product because it is billable and clinically proven, not because it is “innovative”.

5. Spain

Southern Europe’s fastest riser

Why Spain works

  • Regional ecosystems (Barcelona, Valencia, Basque Country) punching above their weight.
  • Cheaper to operate than Western Europe.
  • Private insurers and provider networks actively digitising.

Best for

Chronic-care platforms, elderly-care tech, data platforms, early-stage medtech.

Funding & Launchpads

Example Startup

SAVANA Valuation: ~$200M

One of Europe’s most advanced AI/NLP players extracting structured insights from unstructured EHR data. Deployed in 150+ hospitals across 15 countries

Caveat

Spain is a 17-region market. Choose wisely for your regulatory environment and talent pool availability.

6. Switzerland

Small market, big credibility

Why Switzerland works

  • Europe’s densest medtech ecosystem.
  • Rich reimbursement environment.
  • High willingness to pay.

Best for

Device + digital hybrid models, precision diagnostics, biomarkers.

Funding & Launchpads

Example Startup

Cequr Valuation ~$600M
Wearable insulin delivery.

Caveat

You go to Switzerland for credibility, not market volume.

And now… The CEE Region

The “build-smart, validate-fast” zone investors keep overlooking

CEE is not one region, it’s an efficiency laboratory. If Western Europe drowns you in process, CEE saves you with pragmatism.

Best for

  • AI/engineering-heavy products
  • Cost-effective clinical pilots
  • Digital & device hybrid development
  • Workflow automation
  • Early validation with real hospitals

Below is the full CEE landscape with funding sources, launchpads and example startups.

Poland. The quiet giant

Funding & Launchpads

Example:

DocPlanner: Valuation: ~$1.1B
One of Europe’s biggest healthtech exports.

Why it works

Big market, strong talent, private care booming.

Czech Republic – Medtech discipline, startup speed

Funding

Example:

Carebot Valuation: Estimated €8–12M range (seed stage but strong clinical adoption)
AI radiology assistant (clinical decision support)

Why it works

Top-tier clinical research + reasonable procurement.

Slovakia, a tiny market with great AI talent

Funding

Example:

Powerful Medical Valuation: ~$60–80M
AI ECG interpretation.

Why it works

High clinical AI capacity, very open to digital pilot projects.

Hungary, The algorithm factory

Funding

Example:

Turbine.AI Valuation: ~$80–120M
Virtual cell simulation for drug discovery.

Why it works

Some of Europe’s best AI/ML maths talent.

Romania. The rising talent powerhouse

Funding

Example:

Telios Care Valuation: ~$20–30M
Telehealth leader for employers and insurers.

Why it works

Massive engineering pool, fast-moving private health sector.

Baltics. Where digital health actually behaves like digital health

Funding

Example:

Antegenes (Estonia)
Genomic cancer risk diagnostics (valuation undisclosed, strong EU scaling trajectory)

Why it works

Digital-first culture + world-leading infrastructure.

So where should you start?

If your solution is…
Data heavy → Nordics / Baltics
Reimbursement heavy → France / Germany
Consumer-forward → UK
Hardware + software → Switzerland / Ireland
Cost-sensitive early-stage → Poland / Romania / Spain / Portugal

Europe rewards founders who pick the right first country — not the closest or the coolest.
Start where the system actually wants what you’re building.

Europe HealthTech Market Selection Table (2025)

RegionBest ForStrengthsRisks / Caveats
FranceDTx, diagnostics, digital careStrong reimbursement, centralised system, public fundingBureaucracy and long cycles
NordicsRemote monitoring, preventive care, data platformsFast pilots, high trust, digital literacySmall markets, must scale outbound
United KingdomAI health, consumer, care platformsStrong VC ecosystem, NHS validation, growing private sectorNHS timelines unpredictable
GermanyMedtech, diagnostics, hospital ITBiggest EU health budget, strong reimbursementCompliance-heavy, slow procurement
SpainChronic care, elderly care, health dataLower costs, regional innovation hubsFragmented procurement
SwitzerlandDevices + digital, precision diagnosticsGlobal medtech hub, strong reimbursementSmall domestic market
PolandWorkflow automation, AI tools, B2BLarge population, strong engineeringRegionalised buying, variability
Czech RepublicDevices + software, clinical validationStrong research base, quick adoptersLimited consumer market
SlovakiaAI diagnostics, early pilotsHigh technical talentVery small market
HungaryAI/ML healthtech, data infraTop maths/AI talentRegulatory unpredictability
RomaniaTelehealth, digital care, SaaSLarge engineering poolPublic sector slow
BalticsData platforms, interoperabilityDigital-first systems, fast pilotsMicro-markets

Categories
Digital Health MedTech

2024 vs 2025: Where the Money’s Really Coming From in European HealthTech

If you work in HealthTech in Europe, you’ve probably noticed something strange. 2024 felt like the world was ending, yet the actual numbers say something very different.
Capital didn’t disappear — it simply stopped tolerating nonsense.

Now, in 2025, the money is flowing again, and aggressively so.
But it’s flowing selectively.

2024: The Great Reality Filter

Forget the headlines about a funding collapse. What actually happened in 2024 was a reset of expectations. Investors didn’t stop writing cheques, they just stopped writing them for half-baked pitch-deck poetry.

A study analysing ~1,300 funding rounds across European biotech, medtech and digital health showed fewer deals, but bigger ones.
Median pre-seed funding actually rose ~15.7% YoY to around €870K, which doesn’t sound like panic to me.

And Q3 2024 alone brought nearly US$2B in HealthTech investment..
The hubs were the usual suspects: UK, Germany, France, with Spain, Portugal and the Netherlands quietly moving up the table.

The hottest segments?
Oncology, biotech and AI-powered diagnostics: areas where outcomes are measurable and regulatory paths exist.

Karista summed up the year perfectly: a “reality filter.

It was not a crash, but a sorting mechanism.
The pretenders left the room, the contenders stayed.

2025: Capital Is Back, Smarter

Then 2025 arrived and the mood changed fast.

According to Galen Growth, European digital health funding grew 52% YoY in H1 2025, totalling around US$3.4B across 182 deals. Europe is representing 26% of global funding

Figure 1. European Digital Health Funding Trend 2021–2025 (Indexed)
Indexed view using 2021 baseline of 100. 2025 funding growth (52% YoY, US$3.4B H1) based on Galen Growth. 2021–2024 values illustrative, derived from partial public snapshots.

Figure 1. European Digital Health Funding Trend 2021–2025 (Indexed)
Indexed view using 2021 baseline of 100. 2025 funding growth (52% YoY, US$3.4B H1) based on Galen Growth. 2021–2024 values illustrative, derived from partial public snapshots. Source: disrupting.healthcare

And the average deal size jumped to roughly US$18.6M, nearly three-times the Q2 2024 level.

Figure 2. Average Deal Size — 2024 vs 2025 (Relative)
Based on publicly reported 3× YoY increase in average deal size (Galen Growth, Healthcare.Digital). Source: disrupting.healthcare

Even more striking: ~65% of all capital went to AI-powered clinical and diagnostic platforms.

Figure 3. Capital Allocation by Segment — H1 2025
~65% of capital allocated to AI-driven clinical & diagnostic platforms (Galen Growth, H1 2025). Source: disrupting.healthcare

The investment ecosystem has expanded dramatically:
254 active digital-health-focused funds in 2025 vs 84 in 2021.

This isn’t a hype revival, but it’s conviction capital. Investors aren’t betting on stories. They’re betting on proof.

The Difference in One Sentence

2024 sorted the real players from the noise.
2025 is paying the real players.

Metric2024 2025
Deal flowReduced volume Clear acceleration
Average deal sizeReduced volume €16M
Funding FocusBiotech, oncology, med-deviceAI-clinical & diagnostic
Investor tolerance Traction required Validation required
Entry barrier Brutal Still high, but capital available
Capital geography UK, DE, FR Broader pan-EU activity

What to Do With This Information

If you’re a founder:

  • If you have validation: raise now.
  • If you only have a concept deck: don’t waste everyone’s time.
  • Mix non-dilutive + VC — it’s no longer optional.

If you’re an investor:

  • Europe is still undervalued vs the US — genuine upside exists.
  • Secondary acquisitions are coming.
  • AI is not a theme — it’s now an allocation mechanism.

It’s not 2021 again. 2025 is healthier, clearer, and honestly, more exciting.

Data Methodology & Transparency

The charts included in this article illustrate directional trends in European HealthTech funding rather than precise historical totals. Publicly available data does not provide continuous, fully aggregated funding records across all HealthTech sub-segments (digital health, medtech, diagnostics, biotech) from 2021 through 2024.

2025 funding values, including YoY growth, deal count and sector capital allocation are based on publicly reported figures from Galen Growth (H1 2025): European Digital Health Bucks the Global Trend

The indexed 2021–2025 funding trend chart is a normalized illustrative representation designed to highlight directional recovery and acceleration rather than exact historical volumes. Earlier periods (2021–2024) are estimated using partial public snapshots and normalized to a 2021 baseline of 100 to enable comparison.

The chart communicates trajectory, not absolute values.
Where precise historical figures are required (e.g. investor deck, financial report), a consolidated dataset should be constructed from Dealroom / PitchBook / CB Insights / Crunchbase Pro and national grant databases.

Next in This Series

Best Places to Launch or Scale a HealthTech Company in Europe

Spoiler: it is definitely not always London or Berlin.

Categories
Digital Health MedTech

Who’s Funding the Boom?

The VCs, public funds, and CVCs writing cheques in European healthtech (2025 edition)

Healthtech funding in Europe is accelerating again.
After a cautious 2023, investment rebounded to $4.8 billion in 2024, and Q1 2025 alone brought in $4.3 billion. Healthtech now captures 30 to 35% of all venture activity across the continent. But who’s actually writing those cheques?

This post breaks down the capital stack behind Europe’s digital health growth: venture capital, public funds, and corporate/strategic investors. Whether you’re raising or deploying capital, here’s who you need to know in 2025.

1. Venture Capital: Still the Primary Engine

Venture capital is behind most of the major healthtech rounds in Europe. From seed to Series C, VCs provide the scaling fuel, validation, and network access.

Top 5 VCs Investing in European HealthTech:

  • Sofinnova Partners: Paris-based life sciences fund active in healthtech, diagnostics, and therapeutics.
  • Octopus Ventures: UK fund with a strong healthtech thesis, including femtech and digital care.
  • Speedinvest: Vienna-based early-stage investor with a focus on digital health and care platforms.
  • EQT Life Sciences: Nordic growth-stage investor in diagnostics, medtech, and health platforms.
  • Calm/Storm Ventures: Focused on pre-seed and seed-stage digital health across underserved areas like paediatrics and mental health.
Who are the best VCs for digital health in Europe?

Those five are consistently active in 2024-25, spanning early to growth-stage capital.

2. Public & EU Funding: De-risking and Catalysing Growth

Public funding rarely leads rounds, but often enables them. Grants, co-investments, and match funding are key to bridging early clinical stages and reimbursement pilots.

Key Public Funding Sources for HealthTech in Europe:

  • Horizon Europe: EU R&D programme with dedicated tracks for health and medtech.
  • EU4Health: €5.3 billion programme for health system resilience and digitalisation.
  • European Investment Bank (EIB): Committed €70 billion (2025-27) to tech, including health innovation.
  • Bpifrance: France’s national investment bank, active in medtech, digital health, and AI.
  • Innovate UK: Grant and co-investment body supporting UK healthtech pilots and R&D.
Can you get EU grants for a healthtech startup?

Yes. Programmes like Horizon Europe, EIC Accelerator, and EU4Health fund clinical validation, digital health infrastructure, and medtech scale-up.

3. Corporate Venture & Strategic Investors: Validation with Capital

CVCs and strategic investors are increasingly active in Series B+ deals. They offer more than capital, including access to clinical settings, distribution, and potential M&A.

Key Corporate Venture Funds:

Do corporates invest in digital health startups in Europe?

Yes. In 2025, CVCs from pharma, medtech, and insurance are increasingly co-investing in digital health.

Estimated Funding Breakdown (2025):

SourceShare EstimateRole
Venture Capital / PE65–75%Lead rounds, scale capital
Public Funds / Grants (EU + National)10–20%Early-stage, pilots, non-dilutive
Corporate / Strategic / CVC10–15%Strategic fit, late-stage, distribution

Insight: Most healthtech rounds in 2025 involve blended capital: a VC lead, public match-funding, and a strategic partner.

Strategic Takeaways

Founders: Match your capital to your stage. Grants and public co-investments work best pre-revenue or pre-regulatory.
Investors: Watch for startups with public funding traction—often a good de-risking signal.
Operators: CVCs are gatekeepers to reimbursement and go-to-market. Engage early, but be realistic on timing.

Next up: How the funding mix changed between 2024 and 2025, and what it signals about the future of EU healthtech capital.

Categories
Digital Health MedTech

The Top 10 Most Valuable HealthTechCompanies in Europe (2025)

Valuation isn’t everything but in healthtech, it tells you who’s still scaling

Let’s not pretend valuation is the ultimate success metric. But it is a decent proxy for where capital, confidence and commercial traction are flowing. Especially in a market as fragmented and overregulated as European healthcare.

The 2025 leaderboard of Europe’s top 10 most valuable healthtech companies.


Not biotech. Not pharma. Just tech-enabled health. Companies at the intersection of software, care and medical delivery models. Most are private. A few are flying under the radar. And yes, Finland opens the list.

1. Oura Health (Finland)

Valuation: US$11 billion (Sep 2025)
What it does: Smart wearable ring + health analytics
Why it matters:
Europe’s wearables play moving into serious health data.

2. Doctolib (France)

Valuation: US$6.4 billion (2025 ranking) 
What it does: Appointment booking and telehealth platform for European health systems.
Why it matters: A dominant platform reaching scale across French & German markets, signalling what digital
health infrastructure looks like in the EU.

3. Sword Health (Portugal)

Valuation: US$4 billion (June 2025 funding round) 
What it does: AI-enabled digital therapy / musculoskeletal care
Why it matters: Bridges digital therapeutics and service delivery with high value healthcare cost savings.

 4. Kry International AB (Sweden)

Valuation: Reported ~US$2 billion 
What it does: Telemedicine/virtual primary care (marketed as “Livi” in UK/France)
Why it matters: One of the larger pan-European virtual care plays.

5. Cera Care (UK)

Valuation: Reported >US$1 billion (source)
What it does: Tech enabled home care & community services
Why it matters: A service delivery business scaling across UK homecare, a difficult but high impact node of the health system.

6. Flo Health (UK)

Valuation: ~US$1 billion
What it does: Women’s health (cycle tracking, fertility, health analytics)
Why it matters: Rare consumer digital health “scale” platform in Europe with global ambitions.

7. Neko Health (Sweden)

Valuation: ~US$1.8 billion
What it does: Full body scanning diagnostics with AI
Why it matters: Diagnostics and proactive screening is one of the less hyped but high upside segments in EU healthtech.

 8. Cequr SA (Switzerland)

Valuation: ~US$600 million (estimate)
What it does: Wearable insulin delivery device + patient engagement
Why it matters: Device + digital combo in chronic disease management

9. Hilo Health (Switzerland/Spain)

Valuation: ~US$300 million (estimate)
What it does: Continuous blood pressure monitoring without cuffs
Why it matters: Remote monitoring is crowded, but clinically meaningful, reimbursable models still rare.

10. Nobi BV (Belgium)

Valuation: ~US$150 million (estimate)
What it does: Smart ambient care sensors for elderly living at home
Why it matters:
A realworld aging play; modest valuation, but high relevance for Europe’s demographic shift.

What this list tells us?

Valuation follows integration. The highest valued companies are those who figured out how to embed into care delivery systems, not just launch a product or service.
It’s not just software. Many of the names here incorporate hardware or device components, but the business model leads with experience, outcomes, and scale.
Europe has range. From Portugal to Sweden to France, the value creation is not limited to London/Berlin (though they still matter).
But caution remains. Private valuations are fluid. Some said “decacorn” for Oura a year ago; latest official validated valuation is half of it at around ~$5.2bn the jump to ~$11bn comes from news speculation.

One Last Note

This list isn’t final, and it will change, maybe an hour after the publication. Private valuations shift. Some firms may consolidate or pivot. But if you’re looking to invest, compete or expand — these are the healthtech
companies dominating European healthtech headlines for now.

Next up: where the money’s coming from — and who’s still writing the big cheques.

This content has been enhanced with GenAI.

Categories
Digital Health MedTech

Mapping the European HealthTech Goldmine

What’s scaling, who’s paying, and why you should care

Let’s start with a question.
What do Oura, Sword Health, and Doctolib have in common?

If you said “healthtech unicorns” you’re technically right, but that’s not the real answer.
The real answer: they’re European, they’re growing like weeds, and most investors or founders still talk about them like they’re niche side projects.

Which is odd. Because these are the companies quietly shaping the future of healthcare on the old continent, while half the market’s still arguing about whether DiGA is dead or just very German.

So, I’ve put together something to help.

This is Mapping the European HealthTech Goldmine.
A five-part series for anyone building, backing, or expanding healthtech in Europe.

Why now?

Because the money’s back.

After the hangover that was 2023, last year saw European healthtech bounce to around $4.8 billion in VC funding. This year? $4.3 billion in Q1 alone, and that’s not even counting what gets tucked into medtech, diagnostics, or things with “AI” bolted on just to close a round.

The capital is flowing. But, and this is where it gets interesting, it’s not flowing evenly.

It’s going to:

  • A handful of markets (Finland? Really? Yes.)
  • A small set of models (wearables, MSK, diagnostics-as-a-service)
  • And companies that figured out how to integrate with public health systems without losing their will to live.

What you’ll actually get

No vague “trends”. No breathless “disruption” language, this you have in the name of this website. I offer just five posts that get to the point:

  1. The Top 10 Most Valuable HealthTech Companies in Europe
    Valuation league table, explained, and why some are quietly stalling.
  2. Who’s Funding the Boom?
    The VCs, public funds, and CVCs writing cheques in 2025.
  3. 2024 vs 2025: Where the Money’s Really Coming From
    VC vs grants vs corporate with actual (well, approximated) numbers.
  4. Best Places to Launch or Scale a HealthTech Company in Europe
    Spoiler: it’s not always Berlin or London.
  5. What Europe’s HealthTech Winners Did Differently
    (Besides surviving long enough to be acquired.)

Who this is for

If you’re a founder, an investor, or someone trying to scale something in European healthcare without losing your shirt — this is for you.

Especially if you’re tired of reading loud headlines about $20M Series A rounds in the US and wondering why your reimbursement pilot takes 18 months and a PowerPoint deck for the bored Ministry officials.

Read it, steal ideas from it, or forward it to your CFO

The first post, the top 10 most valuable healthtech companies in Europe goes live next.

After that, one post a week, give or take.
Short reads. Linked data. Unapologetically European perspective.

If that sounds useful, subscribe, bookmark, or just come back with coffee.

See you in the series.